FRISS
13.6.2019 07:02:06 CEST | Business Wire | Press release
Eurolife ERB, a Fairfax company, has won the IMPACT BITE (Business IT Excellence) Awards 2019 in the category IT Business Process Improvement, for its AI approach to assess risks and reduce the likelihood of fraud. The IMPACT Bite Awards is open to all companies, across industries, who have successfully integrated IT & tech systems and/or have taken initiatives in the domains of IT & Comms infrastructure that support their business goals. Eurolife ERB entered the competition with their successful implementation of the FRISS solution for automated fraud prevention. Thanks to this solution they lowered their loss ratio, enabled digital transformation and improved their customer experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190612005694/en/
Eurolife ERB, a leading player in the Greek insurance market, has the goal to reduce the risk it faces in cases of fraud involving future indemnities in the car insurance industry. Through the use of Artificial Intelligence, Eurolife ERB, in close cooperation with FRISS, has created a process of automated, more detailed risk assessment control, seeking faster, more complete and safer processing. This provides them with better customer service while contributing significantly to maintaining a net portfolio.
John Kostoglou, CIO of Eurolife ERB: “I’m very proud that we have won this award. It is great to see that our focus on innovation and digital transformation get recognized. For every insurance company the possibility of fraud is very high, in particular for contracts relating to the car industry. With the help of FRISS we are able to detect high risks and fraud in real-time. With this state-of-the art technology we save time and money for our customers.”
Simon Staadegaard, Sales Manager at FRISS, states: “We are delighted to see that our efforts to detect fraud and support honest insurance pay off. The recognition by IMPACT shows that the insurance industry really values the power of our AI solutions that are combined with our expert industry knowledge. The project with Eurolife ERB went smoothly. It was delivered on time and within budget. We look forward to a bright and fraud free future together.”
About Eurolife ERB
Eurolife ERB Insurance Group is a member of Fairfax Financial Holdings Ltd., who, through its subsidiaries, operates in insurances, reinsurance and investments’ management. Eurolife ERB Insurance Group, through its subsidiaries in Greece and Romania, designs, markets and promotes advanced products and services that meet the full range of contemporary insurance needs. Group companies in Greece include Eurolife ERB Life Insurance SA, Eurolife ERB General Insurance SA and ERB Insurance Brokers SA. A leading player in the bancassurance market, the Group has established a broad network of affiliated insurance agents across Greece. Group companies in Romania include Eurolife ERB Asigurari de Viata and Eurolife ERB Asigurari Generale. Eurolife ERB Insurance Group consistently maintains strong earnings levels and capital reserves in excess of European regulatory requirements, so as to always fulfil its responsibilities towards its clientele. Understanding its role in the society, Eurolife ERB Insurance Group is committed to give back to the communities a part of its profits per year. Through its corporate social responsibility program, the Group implements actions: (a) for quality of life and wellness, (b) for the promotion of education and culture, (c) for entrepreneurship and economy, supporting more choices and optimism for the future.
For more information, visit eurolife.gr
About FRISS
FRISS has a 100% focus on automated fraud and risk detection for P&C insurance companies worldwide. The AI-powered detection solutions for underwriting, claims and SIU have already helped 150+ insurers to grow their business. FRISS detects fraud, mitigates risks and supports digital transformation. Insurers go live within 6 months, with fixed price projects, and realize an ROI within 12 months. The FRISS solutions help to lower the loss ratio, enable profitable portfolio growth, and improve the customer experience. www.friss.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190612005694/en/
Contact:
Ruud van Gerwen PR & Product Marketer at FRISS +31 30 767 0352 Ruud.van.gerwen@friss.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom